安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ruxolitinib - Wikipedia
In the European Union, ruxolitinib cream is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age
- Ruxolitinib: Uses, Dosage, Side Effects Warnings - Drugs. com
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease The brand name is Jakafi, and it is an oral tablet that is taken twice a day
- Jakafi® (ruxolitinib) Prescription Medicine
Learn about Jakafi® (ruxolitinib) – Used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not tolerate it, and adults with certain types of myelofibrosis
- Ruxolitinib (oral route) - Side effects dosage
Ruxolitinib is used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis
- Ruxolitinib: MedlinePlus Drug Information
Ruxolitinib is in a class of medications called kinase inhibitors It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply
- JAKAFI (Ruxolitinib) Label - Food and Drug Administration
Ruxolitinib is the predominant entity in humans representing approximately 60% of the drug-related material in circulation Two major and active metabolites were identified in plasma of healthy
- Ruxolitinib (Jakafi): Uses Side Effects - Cleveland Clinic
Ruxolitinib is a medication that stops proteins in cells from growing It treats myelofibrosis, polycythemia vera and graft-versus-host disease
- Jakafi (ruxolitinib): Uses, Side Effects, Interactions . . . - WebMD
Jakafi (ruxolitinib) is commonly used to treat certain types of blood cancers, including myelofibrosis (MF) and polycythemia vera It is also used to treat graft versus host disease (GVHD)
|
|
|